Listen to this article · 8 min listen

When you’re trying to bring AI into a clinical workflow, you’re going to get hit with a firehose of vendor claims. The real challenge for any health system, buyer, or procurement team wading through this crowded field is figuring out what to do when a vendor’s glowing internal validation report gets contradicted by an independent study. This has direct consequences for patient safety, where your money goes, and whether anyone will trust these tools in the first place. The point isn’t to declare one side “right” and the other “wrong.” It’s to dig into the methods, the patient populations, and the success metrics that each side used to get their numbers.

The Nuance of Discrepancy: Population and Time Window

So, a vendor shows you amazing performance stats for their new AI, but then an independent study comes out with a completely different, usually worse, story. Your first question should be about the patients and the timeframe. AI models are incredibly sensitive to the data they’re trained on versus what they see in the wild. A model that works perfectly on one hospital’s patient demographic might fall apart completely in another. Take the Epic Sepsis Model (ESM), an algorithm meant to flag patients at risk for sepsis. Epic Systems has done its own internal validations and keeps updating the model, but independent research, including studies in JAMA Internal Medicine, found major performance gaps when the ESM was used in the real world Independent study on Epic Sepsis Model performance. These studies, even recent ones looking at the updated model, consistently point to problems like a high rate of false alarms, a low positive predictive value (meaning most alerts are noise), and little actual effect on patient outcomes, with performance varying a ton between hospitals. The key difference is often the patient cohorts. Was the vendor’s validation done on a clean, homogeneous dataset from a single institution (maybe the one where it was built?), while the independent study tested it across a dozen messy, diverse hospitals with different patient mixes and EHR setups? The evaluation’s time window matters, too. An AI’s performance can rot over time in a process called algorithmic drift, as the real-world data it sees slowly changes from what it was trained on. A vendor’s validation might be a snapshot of peak performance right after launch, while a study done a couple of years later is measuring what’s left after drift has set in.

Defining Success: Model Performance vs. Clinical Utility

You also have to ask what “success” even means in these reports. The numbers might not line up because the vendor and the researcher are measuring two completely different things. A vendor’s sales deck might be full of impressive metrics like a high AUC (Area Under the Receiver Operating Characteristic Curve) or F1-score, which just shows the model is good at telling positive and negative cases apart in a dataset. But an independent study is probably looking at things that matter more to patients and doctors, like did mortality go down, did length of stay decrease, or did this thing just create a mountain of extra work and alert fatigue for the nursing staff? The nH Predict algorithm from UnitedHealth Group is a perfect, if painful, example. It was designed to predict hospital readmission risk, and its internal stats probably looked great on paper. But then independent analysis found the algorithm was racially biased, giving lower risk scores to Black patients even when they were sicker Study on racial bias in nH Predict algorithm. More recently, that same algorithm is at the heart of a class-action lawsuit. The suit claims it was used to deny necessary post-acute care to elderly Medicare Advantage patients, with a sky-high error rate that let the algorithm override what doctors were saying. In this case, the fight was about the ethical and equitable disaster of its real-world use, and the very definition of success from a societal perspective versus a purely cost-cutting one. So, does the vendor’s “success” metric actually line up with your hospital’s goals for patient care and equity? Or is this just a technical debate in a vacuum that ignores the real impact on patients?

Transparency and Rebuttal: The Vendor’s Response

When you present a vendor with a study that contradicts their claims, their reaction is a huge tell for your governance team. Did they publish a detailed, scientific rebuttal that gets into the weeds of the independent study’s methods? Or did they just send out a generic press release restating their original numbers? A good vendor will actually engage with the criticism. They’ll offer explanations for the differences, maybe re-run their own numbers on a different population, or provide more data to back up their claims. You need to see if their rebuttal directly challenges the independent study’s methodology, acknowledging the differences in patient groups, data sources, or what was being measured. A vendor that just waves away outside findings without a real, data-backed counterargument is waving a big red flag about their transparency and their willingness to face their product’s limits. On the other hand, a vendor that gets involved, maybe by funding a new third-party study or collaborating on a new validation, shows they’re committed to evidence, not just marketing. Some companies are already doing this right. Hello Heart, for example, often gets its outcome claims published in peer-reviewed journals like JAMA Network Open and the Journal of the American Heart Association (JAHA) Hello Heart JAMA Network Open study. Publishing results externally, instead of just relying on internal white papers, sets the standard for the kind of proof buyers should be demanding.

A Practical Checklist for Due Diligence

For anyone on a procurement or AI governance team, you need a structured way to handle these situations. When a vendor’s numbers and an independent evaluation don’t match, start asking these questions:

  • Population Alignment: Who were the patients? Compare the vendor’s validation cohort to the one in the independent study, demographics, comorbidities, clinical setting. Are they even in the same ballpark? If not, that could explain everything.
  • Time Horizon: When was the data collected for each study? If there’s a big gap, you have to consider if algorithmic drift is the reason the numbers are off.
  • Outcome Definition: What was each study actually measuring to define “success”? Is the fight about raw predictive accuracy, or is it about whether the tool has a meaningful clinical or equitable impact?
  • Data Sources: Were they pulling data from the same source? Tiny differences in EHR integration, data cleanup, or data quality can throw off the results in a big way.
  • Vendor Rebuttal: Did the vendor publish a point-by-point, methodological response to the study? Or was it just a generic defense of their product?
  • Transparency & Collaboration: Is the vendor willing to show you their validation methods, share raw data (with the right privacy agreements), or work with you on another independent evaluation? Answering these questions systematically lets you get past a simple “believe the vendor” or “believe the study” decision. You can build a much richer picture of what an AI tool can and can’t do, making sure that when you deploy it, it actually helps patients instead of creating new risks or making health inequities worse. The target isn’t to find a flawless AI. It’s to implement clinically sound AI with a clear-eyed view of its performance in different contexts and a solid plan for watching it like a hawk.

Frequently Asked Questions

Why do vendor AI performance claims often conflict with independent study results?

Discrepancies often arise from differences in the patient populations and time windows used for evaluation. Vendors might validate models on homogeneous datasets or shortly after development, while independent studies assess performance across diverse settings or after algorithmic drift has occurred. Additionally, differing definitions of ‘success’ between technical accuracy and clinical utility contribute to these conflicts.

How should we assess the ‘success’ of an AI solution beyond technical metrics?

Beyond technical metrics like AUC or F1-score, evaluate success based on patient-centric outcomes such as reduced mortality, shorter hospital stays, or impact on clinician workload. Critically, consider the AI’s ethical implications, potential for bias, and alignment with your health system’s clinical goals, equity objectives, and operational realities. The nH Predict algorithm’s racial bias highlights the importance of this broader assessment.

What should we look for in a vendor’s response to conflicting independent study findings?

A responsible vendor should provide a specific, methodologically sound rebuttal that directly addresses the independent study’s findings. This includes acknowledging differences in patient populations, data sources, outcome definitions, or evaluation periods. A general objection or reiteration of initial claims without robust, data-driven counter-arguments signals potential issues.

How can we ensure an AI model will perform effectively in our specific clinical environment?

AI models are sensitive to the data they encounter in deployment; a model validated on one demographic or setting may not generalize. It’s crucial to understand if the vendor’s validation population aligns with your health system’s patient demographics and clinical practices. Independent studies across diverse environments can reveal how a model performs beyond its initial, potentially homogeneous, validation.